The Landscape of Clinical Trials for Claudin 18.2-Positive Gastric Cancer

Gastric cancer remains a global health challenge, especially in advanced stages where the prognosis is often guarded. However, the discovery of Claudin-18.2 (CLDN18.2) as a specific therapeutic target is shifting treatment paradigms. Researchers are increasingly prioritizing Claudin 18.2 gastric cancer studies to address the significant unmet medical needs in this patient population.

A recent systematic analysis of the global landscape identified 143 clinical trials targeting this biomarker. While research has surged since 2021, nearly 70% of these trials currently remain in early-phase exploration. Notably, the successful progression of drugs into phase II and III trials indicates a maturing pipeline. For instance, zolbetuximab has recently entered phase IV trials, marking its transition into post-market surveillance and real-world clinical application.

Progress in Claudin 18.2 Gastric Cancer Therapeutic Research

The variety of drug types under investigation reflects continuous innovation. Monoclonal antibodies constitute over 32% of trials, while antibody-drug conjugates (ADCs) represent approximately 26%. Furthermore, CAR-T therapies have gained significant traction, representing over 23% of the current clinical landscape. Other modalities, such as bispecific antibodies and CAR-NK cells, are also entering the arena. Consequently, these diverse strategies offer multiple avenues for personalized treatment.

Geographically, trial activity centers on East Asia, North America, and Europe. China currently leads in both independent and collaborative research efforts. Meanwhile, the United States maintains the broadest international partnership network. This global synergy is essential for accelerating the development of novel therapies. Therefore, patients worldwide may soon benefit from more refined and effective treatment options.

Frequently Asked Questions

What is the clinical significance of Claudin 18.2 in gastric cancer?

Claudin 18.2 is a protein that maintains gastric mucosal tight junctions. In malignant cells, it becomes exposed, allowing targeted drugs to bind specifically to tumor tissue while sparing most healthy organs. This selectivity reduces off-target toxicity and improves the therapeutic index.

Which drugs are currently leading the CLDN18.2 landscape?

Zolbetuximab is the most advanced monoclonal antibody, showing improved survival when combined with chemotherapy in high-expression patients. Additionally, antibody-drug conjugates (ADCs) and CAR-T therapies are showing promising results in early and mid-phase clinical trials for metastatic disease.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Fan X et al. The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer. Am J Clin Oncol. 2026 Feb 24. doi: 10.1097/COC.0000000000001307. PMID: 41734398.


2. Lordick F et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-1668.


3. Shitara K et al. Zolbetuximab plus CAPOX in 1L Claudin-18.2-positive gastric or gastroesophageal junction adenocarcinoma: the phase 3 GLOW study. Nat Med. 2023 Sep;29(9):2133-2141.